Objective: To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
The most dramatic presentation of exudative macular degeneration is the sudden onset of subretinal hemorrhage accompanying the development of choroidal neovascularization. The natural history of such lesions is variable.
1e3 Large hemorrhages are associated with damage or atrophy of the retinal pigment epithelium (RPE) and thus removal with subretinal surgery or pneumatic displacement has been advocated in the past. 4, 5 Intravitreal injection of tissue plasminogen activator has also been used as a sole agent or in combination with pneumatic displacement to facilitate resorption of hemorrhage and prevention of fibrosis formation. 6, 7 Eyes with large subretinal hemorrhage have been excluded from every major therapeutic trial of thermal laser, photodynamic therapy, and agents targeting vascular endothelial growth factor (VEGF).
8e12 Eligibility criteria for the initial clinical trials for choroidal neovascularization (CNV) required that <50% of the lesion area be composed of hemorrhage because of the need to target the area of neovascularization for thermal laser and because of additional concerns about the ability to activate verteporfin in the presence of blood for photodynamic therapy. These exclusion criteria were carried forward to the early phase and registration trials of anti-VEGF agents because of their historical use and because of concerns about the efficacy of pegaptanib, ranibizumab, and aflibercept in the presence of blood. These exclusions have led to a dearth of information regarding the potential for such eyes to respond to treatments, with only a few case series having a small number of patients or short follow-up period providing information on outcomes of anti-VEGF treatment. 13e17 The Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) chose to include eyes with lesions composed of >50% hemorrhage in an effort to understand their response to anti-VEGF therapy and to further guide clinicians in the care of such challenging eyes.
Methods

Study Population for the Clinical Trial
Details of the design and methods for CATT have been published previously.
18e21 Patients were enrolled through 43 clinical centers in the United States between February 2008 and December 2009. Inclusion criteria included age !50 years, presence in the study eye (1 eye per patient) of previously untreated, active CNV secondary to age-related macular degeneration (AMD), and visual acuity (VA) between 20/25 and 20/320 in the study eye. Active CNV was considered present when both leakage on fluorescein angiography (FA) and fluid on time-domain optical coherence tomography (OCT) were documented through central review of images. Fluid on OCT could be within or beneath the retina or beneath the RPE. Either neovascularization, fluid, pigment epithelial detachment, blocked fluorescence, or hemorrhage needed to be under the fovea. Hemorrhage associated with the lesion could be superficial, subretinal, or sub-RPE in location. Hemorrhage was considered to be part of the lesion only when it was contiguous with the total neovascular lesion and the hemorrhage extended beyond the fluorescence of the underlying CNV on FA. During the trial, eligibility criteria were modified to allow lesions composed of >50% blood to study this population specifically. Before October 13, 2008 , study eyes that had neovascular lesions with >50% hemorrhage as part of the lesion were considered ineligible and were excluded from recruitment. The exception to the >50% blood rule was retinal angiomatous proliferations, where the area of superficial hemorrhage associated with the lesion was often >50%. When blood was one of the lesion components, the area of the lesion was classified as <50% blood or ! 50% blood. The study was approved by an institutional review board associated with each center, was compliant with Health Insurance Portability and Accountability Act regulations, and was registered with ClinicalTrials.gov (NCT00593450). All patients provided written informed consent.
Treatment Assignment of the Study Eye
At enrollment, patients were assigned with equal probability to 1 of 4 treatment groups defined by drug (ranibizumab or bevacizumab) and by dosing regimen (monthly or pro re nata [PRN] ). At 1 year, patients initially assigned to monthly treatment retained their drug assignment but were reassigned randomly, with equal probability, to either monthly or PRN treatment. Patients initially assigned to PRN treatment had no change in assignment; they retained both their drug assignment and PRN dosing regimen for year 2.
Study Procedures
At enrollment, patients provided a medical history, underwent VA testing, and had bilateral color stereoscopic fundus photography, FA, and time domain OCT. Follow-up examinations were scheduled every 28 days for 2 years. Eyes assigned to monthly treatment received an injection at every follow-up examination. Eyes assigned to PRN treatment had OCT scans at every examination and were treated if there was fluid by OCT or other signs of active neovascularization. Masked VA acuity examiners tested VA at selected visits, including 52 and 104 weeks. Color fundus photography and FA were performed at 52 and 104 weeks. Masked graders at the Photograph Reading Center assessed color photographs and FAs for features of the neovascular lesion and of AMD. 20 The total neovascular lesion could be composed of CNV and/or scar, serous pigment epithelial detachment, blocked fluorescence, and hemorrhage. For grading of hemorrhage as a lesion component at baseline, the hemorrhage had to extend beyond the fluorescence of the underlying CNV on FA. However, in the follow-up visits hemorrhage situated anywhere in the area of the baseline total CNV lesion or in adjacent areas was graded as part of the total CNV lesion irrespective of the presence of active neovascularization.
Masked graders at the CATT OCT Reading Center identified intraretinal fluid, subretinal fluid, and fluid below the RPE (sub-RPE) and measured the thickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex. 21 
Statistical Analyses
Eyes with lesions composed of !50% blood comprised a group, the B50 group that was compared with the group of all other study eyes, the Other group. Characteristics measured on a categorical scale were compared between groups by chi-square tests. Those measured on a continuous scale were compared with independent t tests. Analyses involving the assigned drug or dosing regimen at year 2 included only those patients who completed !1 visit at a CATT clinical center between weeks 52 and 104, inclusive. Linear (continuous outcome measures) and logistic (dichotomous outcome measures) regression models including interaction terms were used to assess whether the effect of having !50% blood at baseline differed by drug or dosing regimen. Statistical computations were performed with SAS 9.3 (SAS Inc, Cary, NC).
Results
Baseline Characteristics
Eighty-four of 1185 patients (7.1%) enrolled in CATT had neovascular lesions with >50% of the lesion area composed of blood (B50 group). The baseline demographic characteristics were similar between the B50 group and the eyes with no or less blood (Other group; Table 1 ). The mean age of both groups was 79.3 years. Approximately 60% of each group was female. The B50 group had a lower proportion of former or current smokers (46.4% vs 58.0%; P ¼ 0.04). The rates of hypertension and of use of anticoagulant medication were similar between the 2 groups.
At baseline, mean VA was worse in the B50 group (56.0 [z20/ 80] vs 60.9 [z20/63] letters; P ¼ 0.002). Lesion characteristics differed markedly between groups. In the B50 group, CNV size was smaller (0.73 vs 1.83 disc areas [DA]; P < 0.0001) but total lesion size was greater (4.55 vs 2.31 DA; P < 0.0001). The 2 groups had similar rates of occult CNV (51.2% and 59.3%; P ¼ 0.20) and retinal angiomatous proliferation (6.0% vs 11.2%; P ¼ 0.15). Eyes in the B50 group were more likely than the Other group to have a fellow eye with concurrent CNV (40.5% vs 28.6%; P ¼ 0.02).
Total retinal thickness was greater in the B50 group (524 vs 455 mm; P ¼ 0.001). By definition, every eye in the B50 group had hemorrhage as a component of the lesion (!50% of the total lesion area), whereas 30.6% of the Other group (337 eyes) had hemorrhage contiguous with the lesion. Hemorrhage was subfoveal in 50 eyes (59.5%) in the B50 group and in 43 of the Other group (3.9%).
Outcomes During Follow-up
The outcomes of mean VA, mean change in VA from baseline, and proportion of eyes increasing !15 letters were similar between the B50 and Other group at 1 year ( Table 2 ) and 2 years ( Table 3 ). The pattern of increase in mean VA over time in the B50 group was approximately parallel to the pattern in the Other group (Fig 1) , with improving mean VA through 36 weeks and then a plateau through 104 weeks. Increases from baseline in mean VA letter score at 1 year were þ9.3 in the B50 group vs þ7.1 in the Other group (P ¼ 0.22) and at 2 years were þ9.0 vs þ6.1, respectively (P ¼ 0.17). The proportion of eyes achieving !3 lines of improvement (15 letters) in VA at 2 years was 33.3% in the B50 group versus 29.4% in the Other group (P ¼ 0.50). The associations between VA during follow-up and the presence of !50% hemorrhage at baseline did not differ by whether ranibizumab or bevacizumab was used for treatment or by the dosing regimen (P > 0.10).
Assessment of macular morphology was conducted to identify central macular changes that could influence visual outcome (Fig  2) . At both 1 and 2 years, few eyes (<5%) had contiguous blood in either group (Tables 2 and 3 ). Recurrent hemorrhage in the B50 group was uncommon, with 3 eyes developing new hemorrhage between years 1 and 2. Mean total foveal thickness decreased in the B50 group at 1 year by 199 mm and by 168 mm in the Other group (P ¼ 0.15) with little additional change at 2 years. Lesion activity as indicated by fluid on OCT and by leakage on FA was similar between both groups at both 1 and 2 years. Mean lesion size in the B50 group decreased by 1.2 DA at 1 year and at 2 years but increased in the Other group by 0.33 DA at 1 year and 0.91 DA at 2 years (P < 0.001). The B50 group had more foveal scarring at 1 year (29.5% vs 17.4%; P ¼ 0.01) and at 2 years (37.5% vs 21.0%; P ¼ 0.002). Scarring in the foveal center was not restricted in either group to eyes that had blood at the fovea at baseline. Although more eyes in the B50 group were found to have a greater cumulative incidence of RPE tears in the macular region over 2 years (5 [6.4%] of 78 vs 13 [1.3%] of 1028) of the Other group (P ¼ 0.007), the presence of RPE tears involving the center of the macula was equal and uncommon (z1%) in the 2 groups. Analysis of baseline factors predictive of outcome was similar for the B50 group as that previously reported for the group as a whole 22 (Table 4, available at www.aaojournal.org). Factors in the study eye associated with worse VA at 1 year were worse baseline VA and larger CNV area. In the full study population, increased retinal thickness was adversely related to visual outcome. 22 Among patients assigned to PRN treatment for 2 years, B50 and Other groups had a similar number of treatments (12.2 and 13.4, respectively; P ¼ 0.27) .
Discussion
Subretinal hemorrhage associated with exudative AMD may be associated with severe vision loss, fibrous scarring, and RPE atrophy. 3 A study of 41 eyes with subfoveal hemorrhage that comprised >50% of the neovascular lesion found a mean loss of 3.5 (z18 letters) lines at 3-year follow-up, with 44% losing >6 lines (z30 letters).
2 Experimental models have demonstrated mechanical shearing of the outer segments from fibrin adhesions, apoptosis, and retinal toxicity induced by migration of iron into photoreceptors and the RPE as mechanisms of retinal damage caused by the presence of subretinal hemorrhage.
23e25 Treatment for AMD lesions with significant subretinal hemorrhage has included management directed toward elimination or displacement of the hemorrhage. This has ranged from intravitreal injection of tissue plasminogen activator to allow fibrinolysis and absorption of the hemorrhage to subretinal injection of tissue plasminogen activator during a vitrectomy with subsequent pneumatic displacement. 7,26e29 The Submacular Surgery Trial incorporated removal of the entire CNV complex along with the subretinal hemorrhage. In the group with >50% of the lesion consisting of hemorrhage, there was no benefit on vision from surgery. The group included many eyes with worse baseline VA and larger hemorrhagic lesions than the CATT trial and the results are not directly comparable. However, the poor outcome and high rate of complications, with 16% of the treatment group developing retinal detachment versus 2% of the observation group, served as an impetus to study eyes with larger amounts of hemorrhage in the CATT trial. 4 Despite the benefits on vision of anti-VEGF treatment in previous clinical trials, the results of those trials cannot be extrapolated to eyes with greater amounts of subretinal hemorrhage. The CATT trial compared bevacizumab and ranibizumab in 3 different dosing regimens over a period of 2 years and enrolled 84 eyes with exudative AMD where >50% of the lesion area at baseline consisted of hemorrhage (B50 group). This affords the first opportunity to compare the outcome of such AMD lesions with the majority of eyes treated in the trial that had less associated hemorrhage (Other group).
The demographics of the 2 groups were very similar. The groups were compared for risk factors previously associated with presence and severity of subretinal hemorrhage, particularly hypertension and use of anticoagulant therapy. In a retrospective study of 71 consecutive patients with subretinal hemorrhage, use of anticoagulants was associated with a hemorrhage area of 9.71 DA versus 2.99 DA in those not using such medicines. 30 Another study found a relative risk of 11.6 for developing large hemorrhage with the use of anticoagulants in the setting of exudative AMD. They did not find an increase in risk with the use of antiplatelet agents. 31 In the CATT trial, use of anticoagulant medication was comparable between the 2 groups (53.6% B50 vs 52.4% Other). The proportion with hypertension was also very similar (66.7% vs 69.2%).
The most important differences between groups at baseline were VA and lesion size. The B50 group started with a mean VA of 56.0 letters whereas the Other group had Forty-two patients with !50% hemorrhage and 514 patients without !50% hemorrhage were in PRN groups.
Ophthalmology Volume -, Number -, Month 2014 a mean of 60.9 letters. The worse acuity was associated with a mean total lesion area of 4.55 DA versus 2.31 DA for the Other group. Considering the significantly smaller area of visible CNV in the B50 group, the majority of B50 lesions were composed of blood. Both groups had resolution of blood over the course of the first year, with <5% retaining blood as a lesion component at year 1. Recurrence of hemorrhage was uncommon in the B50 group, with only 3 eyes demonstrating this at year 2. Resolution of blood resulted in significant reduction in the overall size of the exudative lesion at year 1 in the B50 group. The total lesion size in the B50 group decreased by 1.2 DA, versus an increase of 0.91 DA for the Other group at year 2. The marked difference between the B50 and Other group in the changes in lesion size during follow-up was similar among the 3 treatment regimens (PRN, monthly, or monthly followed by PRN) and 2 drugs (ranibizumab or bevacizumab). The presence of a greater amount of hemorrhage at baseline was associated with development of fibrotic scar at the center of the macula in follow-up. At year 1, the B50 group had foveal scarring/fibrosis in 29.5% of eyes, whereas the Other group had 17.4%. At year 2, this increased to 38.6% and 21%, respectively. This is more favorable than the 53.3% combined fibrosis and atrophic scar reported in a natural history study of 60 eyes with subretinal hemorrhage. 3 In the CATT trial, center-involving scarring occurred with nearly equal frequency in eyes that had blood located outside the macular center at baseline, as it did in eyes with blood at the center. The development of subretinal fibrosis can occur with regression of CNV in the absence of subretinal hemorrhage. 32 The presence of large subretinal hemorrhage with AMD has been associated with a high incidence of RPE tears. 31, 33 In addition, RPE tears have been described as a potential consequence of anti-VEGF injection, particularly in the setting of large serous pigment epithelial detachment. At baseline, 2.5% of the Other group had serous pigment epithelial detachment involving the center versus no eyes in the B50 group. In follow-up, the B50 group was more likely to have an RPE tear in the macular region (6.4%) than the Thirty-nine patients with !50% hemorrhage and 476 patients without !50% hemorrhage were in PRN groups.
Other group (1.3%), but much less frequently than the 35% reported in association with large hemorrhages in a retrospective study. Importantly, RPE tears in the macular center were equally uncommon in both groups and therefore unlikely to significantly affect the overall visual outcome in the CATT patient groups. Retinal thickness as measured by OCT was greater in the B50 group (524 mm) than the Other group (455 mm) at baseline. Greater retinal thickness at baseline has been associated with worse VA outcome at year 1 in the CATT population overall. 22 There was a marked decrease in retinal thickness over the first year in both groups (À199 and À168 mm). The OCT findings are similar to those described in a small prospective study of ranibizumab treatment for eyes with lesions similar to the B50 group. In this small study, 7 eyes were treated for 1 year and had a mean reduction in thickness of 120 mm. 13 In CATT, there was minimal further change in retinal thickness over the second year. Both groups had gradual and equal reduction of leakage on FA over 2 years, indicating further regression of the CNV lesion.
The pattern of VA improvement was similar in the B50 and Other groups (Fig 1) . The VA results are consistent with previously reported findings from CATT that eyes with worse baseline VA do not achieve the same level of VA as eyes with better VA at baseline. 22 Despite the finding of Figure 1 . Mean visual acuity by presence of ! 50% hemorrhage at baseline. Figure 2 . At baseline, hemorrhage is >50% of the lesion and visual acuity is 55 letters (z20/80). At year 1, hemorrhage has resolved and visual acuity has improved to 69 letters (z20/40). At year 2, the lesion size is stable and visual acuity has decreased 3 letters.
fibrosis at the fovea in 37.5% of eyes in the B50 group at year 2, the VA improved by 9.3 letters at year 1 and 9.4 letters at year 2. The rate of improvement mirrored the group with no blood or <50% blood, which gained 7.2 letters at year 1 and 6.1 letters at year 2. The rate of 3-line improvement (33.3% of B50) was also similar among the 2 groups. Analysis of subgroups supported the finding that VA gains were similar for the B50 group and the Other group whether eyes were treated with ranibizumab or bevacizumab and whether treatment was delivered monthly or PRN. This is consistent with the overall conclusions of the CATT trial but increases the generalizability of the findings. Eyes with exudative AMD with >50% of the lesion composed of blood responded just as well as those with less or no blood. The results described for the B50 group will not be applicable for all AMD lesions with large, subretinal hemorrhages. The thickness of the hemorrhage, a factor that may affect prognosis, was not measured in CATT. 39 The CATT trial inclusion criteria set a minimum corrected VA of 20/ 320. Although the size of some lesions was very large ( 10 DA and 800 mm total retinal thickness), there are subretinal hemorrhages that are significantly larger that may benefit from surgical interventions, such as pneumatic displacement or subretinal evacuation with vitrectomy and gas placement. 7,26e29 The CATT results have shown that treatment with anti-VEGF injections alone may be preferable as the VA outcome was better than reported in most surgical case series and had a much lower complication rate. In addition, previous case series including eyes with substantially worse baseline VA and greater areas of hemorrhage have reported substantial improvements in VA with anti-VEGF treatment.
13e17
Eyes with predominantly hemorrhagic AMD lesions were enrolled in the CATT trial. Hemorrhage as a lesion component was retinal, subretinal, or sub-RPE in location. Response to treatment was demonstrated with elimination of associated hemorrhage, reduction in lesion size, and reduction of retinal thickness over the first year. This resulted in a mean improvement of 9.3 letters. All positive changes were maintained over the second year. Eyes like those enrolled in CATT with exudative AMD lesions composed of >50% blood can be managed clinically in a similar manner as those with no or less blood and can be expected to have a similar improvement in visual outcome.
